Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026The Egyptian Journal of HaematologyOpen Access

Clinico-hematological characteristic, lipogram, and some metabolic alteration in chronic phase chronic myeloid leukemia in a patient treated with Tyrosine kinase inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMona M. SolimanMHMuhamad R. Abdel HameedNHNoha R. Abdel-Rahman Hamzawy

Discussion

Loading...

Member takes

Overview

Prospective study evaluates metabolic markers as predictors of molecular response in chronic myeloid leukemia, suggesting insights for therapy.

Key Points

  • To evaluate clinico-hematological and metabolic markers as predictors of major molecular response in chronic phase CML treated with TKIs.
  • Prospective cross-sectional study involving 60 adults with chronic phase CML.
  • Patients classified by molecular response status after 6 months of treatment.
  • Clinical data and various blood tests were collected at multiple time points.
  • 50 patients achieved major molecular response (MMR), while 10 did not.
  • Neutrophil-to-lymphocyte ratio and TG/HDL ratio were significantly lower in MMR patients (P < 0.05 and P < 0.01, respectively).
  • Age and comorbidity indices were higher in the no-MMR group (P < 0.05).

Cite This Study

Soliman et al. (2026) studied this question.

synapsesocial.com/papers/6a362f92db0793dc1a53702chttps://doi.org/10.4103/ejh.ejh_4_26
View Full Paper
Ask AI
Bookmark
Share